Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 2/20 | 0.56 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.56 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 10/20 | 0.52 |
| ▸ | LMNA | P02545 | 7/20 | 0.52 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | STAT3 | P40763 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL758440 | 0.92 | SMN1; SMN2 (0.49) | STIM1ORAI1ORAI3SMN1; SMN2LMNA | |
| SCHEMBL758443 | 0.90 | L3MBTL1 (0.55) | STIM1ORAI1ORAI3SMN1; SMN2LMNA | |
| SCHEMBL17318575 | 0.89 | SMN1; SMN2 (0.50) | STIM1ORAI1ORAI3SMN1; SMN2LMNA | |
| SCHEMBL756929 | 0.88 | SMN1; SMN2 (0.52) | STIM1ORAI1ORAI3SMN1; SMN2LMNA | |
| SCHEMBL704436 | 0.86 | SMN1; SMN2 (0.65) | STIM1ORAI1ORAI3SMN1; SMN2LMNA | |
| SCHEMBL759187 | 0.85 | SMN1; SMN2 (0.59) | STIM1ORAI1ORAI3SMN1; SMN2LMNA | |
| SCHEMBL30096621 | 0.85 | STIM1 (0.62) | STIM1ORAI1ORAI3SMN1; SMN2LMNA | |
| SCHEMBL757815 | 0.85 | STIM1 (0.56) | STIM1ORAI1ORAI3SMN1; SMN2LMNA | |
| SCHEMBL756313 | 0.85 | STIM1 (0.62) | STIM1ORAI1ORAI3SMN1; SMN2LMNA | |
| SCHEMBL3067259 | 0.83 | STIM1 (0.54) | STIM1ORAI1ORAI3SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113557020-A | Compositions comprising CRAC inhibitors and corticosteroids and methods of use thereof | 瑞真药业公司 | 2021-10-26 | — | — | CN | claimed |
| EP-3849552-A1 | COMPOSITIONS COMPRISING A CRAC INHIBITOR AND A CORTICOSTEROID AND METHODS OF USE THEREOF | Rhizen Pharmaceuticals AG (CH) | 2021-07-21 | — | — | EP | claimed |
| WO-2020053834-A1 | COMPOSITIONS COMPRISING A CRAC INHIBITOR AND A CORTICOSTEROID AND METHODS OF USE THEREOF | RHIZEN PHARMACEUTICALS SA (CH) | 2020-03-19 | — | — | WO | claimed |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-27 | — | — | US | claimed |
| WO-2015187827-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-12-10 | — | — | WO | claimed |
| US-8399436-B2 | N-pyrazolyl carboxamides as CRAC channel inhibitors | GLAXO GROUP LIMITED (GB) | 2013-03-19 | — | — | US | claimed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | claimed |
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | CALCIMEDICA, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | AVENUE CAPITAL MANAGEMENT II, L.P. | 2025-04-17 | — | — | US | disclosed |
| EP-4465988-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | Calcimedica, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| CN-118871110-A | Methods and compositions for treating inflammatory lesions of the lung | 钙医学公司 | 2024-10-29 | — | — | CN | disclosed |
| WO-2023141523-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | CALCIMEDICA, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | AVENUE CAPITAL MANAGEMENT II, L.P. | 2023-04-20 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | GLAXO GROUP LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010122089-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS | GLAXO GROUP LIMITED (GB) | 2010-10-28 | — | — | WO | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
| US-20100273744-A1 | COMPOUNDS | GORE PAUL MARTIN | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12544371-B2 | Methods and compositions for treating acute lung injury and acute respiratory distress syndrome | ORAI1, MAVS, CASR | STIM1 231/4885ORAI1 1/4885ORAI3 632/4885 |
| US-20120053150-A1 | N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS | ORAI1, TRPV1, CACNA1E | STIM1 33/4885ORAI1 1/4885ORAI3 25/4885 |
| US-20250120969-A1 | METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS | IL1B, MAVS, MMP8 | STIM1 852/4885ORAI1 92/4885ORAI3 1278/4885 |
| US-20230120819-A1 | METHODS AND COMPOSITIONS FOR TREATING ACUTE LUNG INJURY AND ACUTE RESPIRATORY DISTRESS SYNDROME | MAVS, ATF1, IL1B | STIM1 943/4885ORAI1 68/4885ORAI3 1408/4885 |
| US-20170114060-A1 | NOVEL EFFECTIVE ANTIVIRAL COMPOUNDS AND METHODS USING SAME | ZC3HAV1, MAVS, EIF2AK2 | STIM1 2753/4885ORAI1 3769/4885ORAI3 1449/4885 |
| US-20100273744-A1 | COMPOUNDS | LTC4S, HRH4, HRH2 | STIM1 2564/4885ORAI1 3127/4885ORAI3 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.